Abstract | INTRODUCTION:
Bleeding symptoms in severe thrombocytopenia range from mild to severe. The aim of this in vitro study was to improve blood clotting and protect against fibrinolysis in reconstituted severe thrombocytopenia blood. METHODS: RESULTS: Spiking thrombocytopenia blood with FEIBA led to reduction of CT. Fibrinogen and FEIBA enhanced α-Angle and MCF both in the absence and in the presence of tPA. LOT values were prolonged by TAFI and to less extent by FEIBA. Dilution of thrombocytopenia blood was followed by reduction of α-Angle and MCF compared to nondiluted blood which partly reversed by either fibrinogen or FEIBA being higher using fibrinogen and FEIBA together. Clot strength was enhanced, and fibrinolysis was inhibited by TAFI. CONCLUSION: The results of this study suggest that combined spiking of blood with fibrinogen and FEIBA may be enough to correct the clot formation disorder in severe thrombocytopenia, whereas in thrombocytopenia and blood dilution, additive inhibition of fibrinolysis may be needed.
|
Authors | B Shenkman, Y Einav, T Livnat, I Budnik, U Martinowitz |
Journal | International journal of laboratory hematology
(Int J Lab Hematol)
Vol. 37
Issue 4
Pg. 521-9
(Aug 2015)
ISSN: 1751-553X [Electronic] England |
PMID | 25651468
(Publication Type: Journal Article)
|
Copyright | © 2015 John Wiley & Sons Ltd. |
Chemical References |
- Blood Coagulation Factors
- prothrombin complex concentrates
- Fibrinogen
- Carboxypeptidase B2
- Tissue Plasminogen Activator
- Calcium Chloride
|
Topics |
- Blood Coagulation
(drug effects)
- Blood Coagulation Factors
(pharmacology)
- Blood Coagulation Tests
(instrumentation, methods)
- Blood Platelets
(cytology, drug effects, metabolism)
- Calcium Chloride
(pharmacology)
- Carboxypeptidase B2
(pharmacology)
- Fibrinogen
(pharmacology)
- Humans
- Models, Biological
- Primary Cell Culture
- Rotation
- Severity of Illness Index
- Thrombelastography
(instrumentation)
- Thrombocytopenia
(blood, pathology)
- Tissue Plasminogen Activator
(pharmacology)
|